Annonce • Jun 24
Qlucore Receives EUR 0.5 Million EU Payment Qlucore has now received the third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments. The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Annonce • Jun 18
Qlucore AB (publ) Receives Approval for EUR 0.5 Million EU Payment Qlucore AB (publ) has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments. The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Following successful progress and review within the agreed project timeline, the next installment is now approved for disbursement. Over the course of the three-year project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics in AML and bladder cancer. The solutions are intended for use in clinical laboratories and will also support the development of companion diagnostics in collaboration with pharmaceutical partners. AML and bladder cancer are areas of particular focus due to their complex RNA profiles. These RNA-based signatures offer significant potential to improve diagnostic accuracy and treatment selection. However, such molecular information is currently not fully utilized in clinical practice. The project aims to enable broader adoption of this data to support more precise, individualized treatment decisions. Research-use-only versions of the tests for AML and bladder cancer have been available since April 2026 through Qlucore Insights. For use in clinical diagnostics, software must comply with IVDR regulations and obtain CE marking. In this project, Qlucore builds on prior investments in Qlucore Diagnostics BCP-ALL, including both software capabilities and a certified quality management system. Qlucore Diagnostics BCP-ALL 1.0 was launched in February 2025 and is currently in use at clinical laboratories. Reported Earnings • May 28
Full year 2026 earnings released: kr1.22 loss per share (vs kr5.10 loss in FY 2025) Full year 2026 results: kr1.22 loss per share. Revenue: kr21.8m (up 18% from FY 2025). Net loss: kr36.5m (loss widened 78% from FY 2025). New Risk • Apr 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Market cap is less than US$10m (kr20.5m market cap, or US$2.24m). Minor Risk Revenue is less than US$5m (kr13m revenue, or US$1.4m). Reported Earnings • Mar 01
Third quarter 2026 earnings released: kr0.077 loss per share (vs kr1.27 loss in 3Q 2025) Third quarter 2026 results: kr0.077 loss per share (improved from kr1.27 loss in 3Q 2025). Revenue: kr7.95m (up 72% from 3Q 2025). Net loss: kr3.31m (loss narrowed 35% from 3Q 2025). Reported Earnings • Nov 28
Second quarter 2026 earnings released: kr0.78 loss per share (vs kr1.48 loss in 2Q 2025) Second quarter 2026 results: kr0.78 loss per share. Revenue: kr4.50m (down 7.8% from 2Q 2025). Net loss: kr23.2m (loss widened 290% from 2Q 2025). Board Change • Oct 24
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Lars Hockenstrom was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annonce • Oct 23
Qlucore AB (Publ) Announces Board Appointments Qlucore AB (publ) at its annual general meeting held on October 23, 2025, approved in accordance with the Nomination Committee's proposal, Lars Pålsson (Chairman), Carl Palmstierna and Kjell Sjöström were elected as members of the Board of Directors. New Risk • Oct 09
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 9x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Earnings have declined by 21% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 9x increase in shares outstanding). Market cap is less than US$10m (kr20.5m market cap, or US$2.15m). Minor Risk Revenue is less than US$5m (kr16m revenue, or US$1.7m). Annonce • Sep 24
Qlucore AB (publ), Annual General Meeting, Oct 23, 2025 Qlucore AB (publ), Annual General Meeting, Oct 23, 2025, at 11:00 W. Europe Standard Time. Location: at the companys office in lund, lund Sweden Reported Earnings • Sep 17
Full year 2025 earnings released: kr5.10 loss per share (vs kr3.89 loss in FY 2024) Full year 2025 results: kr5.10 loss per share (further deteriorated from kr3.89 loss in FY 2024). Revenue: kr18.4m (down 50% from FY 2024). Net loss: kr20.5m (loss widened 31% from FY 2024). New Risk • Sep 02
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (72% average weekly change). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (kr28.8m market cap, or US$3.05m). Minor Risk Revenue is less than US$5m (kr18m revenue, or US$1.9m). Reported Earnings • Jun 19
Full year 2025 earnings released: kr5.10 loss per share (vs kr3.89 loss in FY 2024) Full year 2025 results: kr5.10 loss per share (further deteriorated from kr3.89 loss in FY 2024). Revenue: kr29.2m (down 20% from FY 2024). Net loss: kr20.5m (loss widened 31% from FY 2024). New Risk • May 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr22m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 29% per year over the past 5 years. Market cap is less than US$10m (kr4.79m market cap, or US$492.3k). Minor Risk Revenue is less than US$5m (kr20m revenue, or US$2.1m). Reported Earnings • Mar 27
Third quarter 2025 earnings released: kr1.27 loss per share (vs kr0.69 loss in 3Q 2024) Third quarter 2025 results: kr1.27 loss per share (further deteriorated from kr0.69 loss in 3Q 2024). Revenue: kr7.41m (down 29% from 3Q 2024). Net loss: kr5.12m (loss widened 86% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. New Risk • Mar 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr25m free cash flow). Earnings have declined by 29% per year over the past 5 years. Market cap is less than US$10m (kr12.9m market cap, or US$1.27m). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (kr26m revenue, or US$2.6m). Reported Earnings • Nov 29
Second quarter 2025 earnings released: kr1.48 loss per share (vs kr0.81 loss in 2Q 2024) Second quarter 2025 results: kr1.48 loss per share (further deteriorated from kr0.81 loss in 2Q 2024). Revenue: kr7.02m (down 29% from 2Q 2024). Net loss: kr5.95m (loss widened 83% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings. New Risk • Sep 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr39m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr39m free cash flow). Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (kr29.4m market cap, or US$2.87m). Minor Risk Revenue is less than US$5m (kr37m revenue, or US$3.6m). Reported Earnings • Aug 30
First quarter 2025 earnings released: kr1.87 loss per share (vs kr1.24 loss in 1Q 2024) First quarter 2025 results: kr1.87 loss per share (further deteriorated from kr1.24 loss in 1Q 2024). Revenue: kr5.06m (down 48% from 1Q 2024). Net loss: kr7.53m (loss widened 51% from 1Q 2024). Annonce • Aug 28
Qlucore AB (publ) to Report Q1, 2025 Results on Aug 29, 2024 Qlucore AB (publ) announced that they will report Q1, 2025 results on Aug 29, 2024 Reported Earnings • Jun 04
Full year 2024 earnings released: kr3.89 loss per share (vs kr3.96 loss in FY 2023) Full year 2024 results: kr3.89 loss per share (improved from kr3.96 loss in FY 2023). Revenue: kr39.5m (up 26% from FY 2023). Net loss: kr15.7m (loss narrowed 1.6% from FY 2023). Annonce • May 28
Qlucore Starts Project After Receiving EU Grant to Advance Personalized Cancer Treatment Qlucore has passed the evaluation phase and will receive a prestigious EIC Accelerator grant of EUR 2.5 million to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. In March the grant was made public and Qlucore is now starting the project and has received the first payment. During the project Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for the two cancer types. The project will stretch over three years, with objectives to develop solutions for use by clinical laboratories as well as companion diagnostics (CDx) solutions in collaboration with pharma companies. The selected cancer disease areas are especially suited to the solutions as both cancer types have multiple changes on RNA level that can be utilized to improve diagnosis and treatment. Currently this information is not fully used to provide the right therapy for the right patient. The aim of the project is to change this. Reported Earnings • Mar 01
Third quarter 2024 earnings released: kr0.69 loss per share (vs kr0.72 loss in 3Q 2023) Third quarter 2024 results: kr0.69 loss per share (improved from kr0.72 loss in 3Q 2023). Revenue: kr10.9m (up 17% from 3Q 2023). Net loss: kr2.76m (loss narrowed 4.9% from 3Q 2023). Annonce • Feb 01
Qlucore Diagnostics for Pediatric Leukemia Takes A Significant Step Closer to Ce Marking Qlucore has taken the final major step in the process towards a CE-marked medical device for in-vitro diagnostics by submitting the technical documentation to a Notified Body. The CE marked product, Qlucore Diagnostics, is due to be launched in February 2025. The targeted cancer disease is acute lymphoblastic leukemia (ALL) in children, a condition where mortality and treatment-related complications remain high. In order for a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. The performance study initiated by Qlucore in December 2023 is now complete, with expected positive results. The technical documentation can now be reviewed and approved by the Notified Body. Qlucore has contracted BSI (British Standards Institute) as the Notified Body, and the Institute will conduct a formal review of the product's safety and performance. The result is regulatory approval and CE marking, and the estimated timeframe for regulatory approval of Qlucore Diagnostics BCP-ALL is February 2025. The intended use of the software is to qualitatively analyze the genetic changes that may cause the disease condition BCP-ALL. This is done based on gene activity levels and the identification of gene fusions. The classification into genetic subgroups is performed using a machine learning-based classifier and subsequently, a probability is presented that indicates the likelihood that the patient belongs to one of six defined subgroups. Annonce • Dec 14
Qlucore Announces Swedish Innovation Evaluated for Clinical Diagnosis of Pediatric Leukemia Qlucore has taken a significant and crucial step towards obtaining a CE marked solution, initiating a formal performance evaluation study in Sweden and Denmark. Results from the study are expected early in 2024. The specific cancer to be tested in the study is acute lymphoblastic leukemia (BCP-ALL) in children. Leukemia in children, i.e. BCP-ALL continues to have high mortality rates an treatment-related complications. IVDR regulations for medical devices require products to be CE marked prior to use in healthcare diagnostics. Once the ongoing performance evaluation study is completed, Qlucore will be required to compile a study report and create a technical file that will be submitted to a Notified Body. BSI (British Standards Institute) has been contracted as the Notified Body, and they will conduct the formal review regarding the product's safety and performance. The estimated timeframe for regulatory approval and CE marking of Qlucore Diagnostics BCP-ALL is February 2025. Annonce • Nov 29
Qlucore AB (publ), Annual General Meeting, Sep 09, 2024 Qlucore AB (publ), Annual General Meeting, Sep 09, 2024. Reported Earnings • Nov 29
Second quarter 2024 earnings released: kr0.81 loss per share (vs kr1.03 loss in 2Q 2023) Second quarter 2024 results: kr0.81 loss per share (improved from kr1.03 loss in 2Q 2023). Revenue: kr10.4m (up 52% from 2Q 2023). Net loss: kr3.26m (loss narrowed 22% from 2Q 2023). Board Change • Sep 14
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helle Fisker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Annonce • Sep 08
Qlucore AB (Publ) Appoints Lars Höckenström as A Member of the Board of Directors Qlucore AB (publ) appointed Lars Höckenström as a member of the Board of Directors at its annual general meeting held on September 7, 2023. Reported Earnings • Aug 31
First quarter 2024 earnings released: kr1.24 loss per share (vs kr1.20 loss in 1Q 2023) First quarter 2024 results: kr1.24 loss per share (further deteriorated from kr1.20 loss in 1Q 2023). Revenue: kr10.8m (up 94% from 1Q 2023). Net loss: kr5.00m (loss widened 3.5% from 1Q 2023). New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (kr42.7m market cap, or US$3.94m). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (kr31m revenue, or US$2.9m). Reported Earnings • Jun 01
Full year 2023 earnings released: kr3.96 loss per share (vs kr2.90 loss in FY 2022) Full year 2023 results: kr3.96 loss per share (further deteriorated from kr2.90 loss in FY 2022). Revenue: kr36.4m (up 62% from FY 2022). Net loss: kr15.9m (loss widened 37% from FY 2022). Reported Earnings • Mar 04
Third quarter 2023 earnings released: kr0.72 loss per share (vs kr0.10 profit in 3Q 2022) Third quarter 2023 results: kr0.72 loss per share (down from kr0.10 profit in 3Q 2022). Revenue: kr10.6m (up 48% from 3Q 2022). Net loss: kr2.90m (down kr3.31m from profit in 3Q 2022). Reported Earnings • Nov 30
Second quarter 2023 earnings released: kr1.03 loss per share (vs kr1.62 loss in 2Q 2022) Second quarter 2023 results: kr1.03 loss per share (improved from kr1.62 loss in 2Q 2022). Revenue: kr7.96m (up 53% from 2Q 2022). Net loss: kr4.15m (loss narrowed 2.9% from 2Q 2022). Reported Earnings • Sep 02
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr6.97m (up 173% from 1Q 2022). Net loss: kr4.83m (loss widened 19% from 1Q 2022). Reported Earnings • Jun 12
Full year 2022 earnings released Full year 2022 results: Revenue: kr26.0m (up 54% from FY 2021). Net loss: kr11.7m (loss widened 93% from FY 2021). Reported Earnings • Mar 06
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: kr0.10. Revenue: kr7.15m (flat on 3Q 2021). Net income: kr410.0k (up kr410.0k from 3Q 2021). Profit margin: 5.7% (up from null in 3Q 2021). Revenue was in line with analyst estimates. 
